8 results about "Factor Xa Inhibitor" patented technology

The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Providing a method for testing the efficacy of andexanet. [Solution] This disclosure relates to a kit and method for measuring the potency of an andexanet sample in neutralizing a factor Xa inhibitor and restoring the activity of wild-type factor Xa. This disclosure provides a method for determining the activity of an andexanet sample, comprising: mixing a test sample containing an andexanet with a mixture containing human factor Xa (HFXa) and a direct factor Xa (fXa) inhibitor, wherein the molar ratio of FXa to Xa inhibitor is 0.2:1 to 0.3:1; adding a chromogenic fXa substrate to the mixture, wherein the chromogenic fXa substrate can release a chromophore upon reaction with HFXa; detecting the amount of chromophore released; and calculating the activity of the andexanet sample in releasing HFXa from a direct fXa inhibitor from the amount of chromophore released.

The present invention relates to binding molecules capable of reversing the anti-coagulant activity of direct oral anticoagulants in-vivo and in-vitro. The present invention, more particularly concerns binding molecules for reversing the factor Xa inhibition activity of a factor Xa inhibitor such as in a patient to whom a factor Xa inhibitor is administered. The present invention is further related to binding molecules capable of reversing the anti-coagulant activity of direct oral anticoagulants, for use in medicine and diagnostics. More particularly, the present invention concerns binding molecules for use in the treatment or prevention of bleeding, and for use in the detection and quantification of such molecules, e.g. in human plasma. The present invention further provides a method for detecting a factor Xa inhibitor in a sample.

A pharmaceutical composition comprising glutathione disulfide or pharmaceutically acceptable organic or inorganic salts thereof and glutathione disulfide S-oxide of the structure (I) or pharmaceutically acceptable organic or inorganic salts thereof for eliminating dose-related toxicity of pharmacologically active compounds and enhancing therapeutic activity of pharmacologically active compounds in the treatment of infectious and non-infectious diseases. Typically, the composition contains 0.01-10% of glutathione disulfide S-oxide by weight of the total composition, in addition to a metal (Me) in the form of a complexing compound containing Me-S-glutathione bond, said metal being selected from platinum group elements, typically platinum. The amount of d-metal complexing compound administered to a patient can be 10 ‑3 to 10 ‑15 mol / kg of body weight. The composition can be used in combination with pharmacologically active compounds, which are anticoagulants, factor Xa inhibitors, antibacterial or antiviral agents, to increase their therapeutic activity and eliminate dose-related toxicity.

To provide an antibody for factor xa inhibitor and method for using the same.SOLUTION: One of the major limitations of anticoagulant therapy is the limitation of the ability to rapidly reverse anticoagulant activity in the case of treatment-related bleeding risk and in cases of overdosage or required emergency surgical intervention. Therefore, a specific effective antidote for all forms of anticoagulant therapy is highly desirable. The present invention relates to an antidote to an anticoagulant that targets factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives described herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.SELECTED DRAWING: None

This invention discloses an isolated anti-FXI and / or anti-FXIa antibody or its antigen-binding fragment, which specifically binds to human FXI or FXIa, and provides a drug targeting FXI that effectively prevents or treats thrombosis with minimal side effects to meet medical needs. Because currently approved anticoagulants interfere with hemostasis, leading to an increased risk of bleeding, there is a significant unmet medical need for safer anticoagulants. Although thrombosis can be treated or prevented with anticoagulants (e.g., heparin, warfarin, aspirin, or factor Xa inhibitors), these treatments have significant adverse effects. Genetic and pharmacological evidence in humans and animals suggests that lowering coagulation factor XI (FXI) can successfully prevent and manage thrombosis with minimal bleeding.

Transdermal delivery systems, such as patches, for certain direct factor Xa inhibitors ("FXa"), particularly in the treatment of thrombosis or other conditions where anticoagulants are desired, and for preventing stroke and embolism in people with atrial fibrillation (AF), and methods for making and using such transdermal patches.